4.6 Article

The International Dermatology Outcome Measures Group: Formation of patient-centered outcome measures in dermatology

Journal

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 72, Issue 2, Pages 345-348

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2014.11.002

Keywords

body surface area; Delphi exercises; Dermatology Life Quality Index; disease severity; International Dermatology Outcome Measures; National Psoriasis Foundation; Outcome Measures in Rheumatology; patient-centered outcome measures; Physician Global Assessment; psoriasis; Psoriasis Area and Severity Index; psoriatic arthritis; quality of life

Categories

Funding

  1. National Psoriasis Foundation
  2. Amgen Inc
  3. Janssen
  4. Eli Lilly
  5. Pfizer
  6. VBL Therapeutics
  7. Abbvie
  8. Centocor (Janssen)
  9. Amgen Inc.
  10. Abbott Labs (Abbvie)
  11. Novartis
  12. Celgene
  13. Coronado
  14. Levia
  15. Merck

Ask authors/readers for more resources

As quality standards are increasingly in demand throughout medicine, dermatology needs to establish outcome measures to quantify the effectiveness of treatments and providers. The International Dermatology Outcome Measures Group was established to address this need. Beginning with psoriasis, the group aims to create a tool considerate of patients and providers using the input of all relevant stakeholders in assessment of disease severity and response to treatment. Herein, we delineate the procedures through which consensus is being reached and the future directions of the project.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available